SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel Post author: Post published:December 12, 2023 Post category:uncategorized SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study. You Might Also Like Psilocybin offers fast-acting alternative to traditional antidepressants May 15, 2026 Preclinical research points to a promising new treatment option for pancreatic cancer patients November 11, 2023 Study: Environmental and social adversities double heart disease risk March 27, 2024
Preclinical research points to a promising new treatment option for pancreatic cancer patients November 11, 2023